Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. (Q50851356)
Jump to navigation
Jump to search
scientific article published on 8 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. |
scientific article published on 8 July 2013 |
Statements
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study (English)
Catherine Thieblemont
Elisabeth Wassner-Fritsch
Franck Morschhauser
Philippe Solal-Céligny
Thierry Lamy
Hervé Tilly
Guiyuan Lei